Sarepta Therapeutics appoints Michael Severino as new CEO

Sarepta Therapeutics has appointed Michael Severino, former CEO of Tessera Therapeutics, as its new chief executive, replacing the retiring Doug Ingram. The change comes as the Duchenne muscular dystrophy drugmaker contends with a significant stock price decline since early 2025, ongoing questions about its treatments' effectiveness, and clashes with US regulators over its gene therapy's safety.

Michael Severino appointment

• ▪Michael Severino's appointment as CEO of Sarepta Therapeutics is effective July 28, 2026
• ▪Sarepta Therapeutics appointed Michael Severino as its new chief executive officer
• ▪Michael Severino was formerly the CEO of Tessera Therapeutics and an executive at AbbVie Inc.

Doug Ingram retirement

• ▪Doug Ingram led Sarepta Therapeutics as CEO for nearly a decade
• ▪Michael Severino is replacing Doug Ingram, who announced his retirement earlier in 2026

Duchenne muscular dystrophy treatments

• ▪Sarepta Therapeutics is a maker of treatments for Duchenne muscular dystrophy
• ▪Under former CEO Doug Ingram, Sarepta Therapeutics secured approval for three Duchenne treatments
• ▪The effectiveness of Sarepta Therapeutics' Duchenne treatments has faced ongoing questions

Gene therapy safety scrutiny

• ▪Sarepta Therapeutics has faced regulatory scrutiny over the safety of its gene therapy
• ▪Sarepta Therapeutics has experienced a period of clashes with US regulators

Stock price decline

• ▪STAT News described Sarepta Therapeutics as a "bruised" maker of Duchenne treatments
• ▪Sarepta Therapeutics' share price has fallen significantly since the beginning of 2025